50616
document
Low-dose clonidine administration in the treatment of mild or moderate essential hypertension : results from a double-blind placebo-controlled study ( Clobass ) . The Clobass Study Group . Five hundred and fifty-nine hypertensive outpatients with diastolic blood pressure between 95 and 110 mmHg participated in this double-blind , placebo-controlled , multicenter study . Eligible subjects were randomly allocated to receive either clonidine ( 75 micrograms twice daily ) or a placebo . After 4 weeks , 'responders ' to treatment ( diastolic blood pressure reduced to less than or equal to 90 mmHg or by greater than or equal to 10 mmHg ) were kept on monotherapy and checked at 4-weekly intervals for another 3 months . Non-responders were given 15 mg chlorthalidone and were also checked for a further 3 months . At the end of the first month , 54.2 % of the subjects were responders to clonidine and 41.5 % were responders to the placebo ( P less than 0.05 for both groups ) . Of the remaining patients , 69.0 % became responders to clonidine plus chlorthalidone , whereas only 34.7 % were responders to placebo plus chlorthalidone ( P less than 0.01 for both groups ) . Withdrawals from the study because of excessive diastolic blood pressure levels were about eight times less frequent among the subjects treated with clonidine , either alone or with chlorthalidone . Dry mouth was twice as frequent in the clonidine-treated patients , but there was no significant difference in the incidence of all side effects or the number of withdrawals from the study because of side effects between the two groups . We conclude that low-dose clonidine is effective in the treatment of mild or moderate hypertension . Clonidine-related side effects are still evident , but the overall tolerance profile for this reduced dosage of the drug appears to be favorable .
50617
Intervention_Pharmacological
clonidine
50618
Intervention_Control
placebo-controlled
50619
Intervention_Control
placebo-controlled
50620
Intervention_Pharmacological
clonidine
50621
Intervention_Control
placebo .
50622
Intervention_Pharmacological
monotherapy
50623
Intervention_Pharmacological
chlorthalidone
50624
Intervention_Pharmacological
clonidine
50625
Intervention_Control
placebo
50626
Intervention_Pharmacological
clonidine
50627
Intervention_Pharmacological
chlorthalidone
50628
Intervention_Control
placebo
50629
Intervention_Pharmacological
chlorthalidone
50630
Intervention_Pharmacological
clonidine
50631
Intervention_Pharmacological
chlorthalidone .
50632
Intervention_Pharmacological
clonidine-treated
50633
Intervention_Pharmacological
clonidine
50634
Intervention_Pharmacological
Clonidine-related
50635
Outcome_Physical
diastolic blood pressure
50636
Outcome_Other
excessive diastolic blood pressure levels
50637
Outcome_Adverse-effects
Dry mouth
50638
Outcome_Adverse-effects
side effects
50639
Outcome_Other
number of withdrawals
50640
Participant_Condition
mild or moderate essential hypertension
50641
Participant_Sample-size
Five hundred and fifty-nine
50642
Participant_Condition
outpatients with diastolic blood pressure between 95 and 110 mmHg